CHEST Research Letter examines geographic reach and eligibility criteria in COPD trials
A Research Letter in the journal CHEST assessed recruitment centre locations and eligibility criteria in phase III/IV trials of single-inhaler triple therapy and biologics for COPD.
“to assess how generalizable and equitable these recent trials are”— CHEST
The American College of Chest Physicians (CHEST) said on X that a Research Letter in its journal, CHEST, has evaluated the geographic distribution of recruitment centres and the inclusiveness of eligibility criteria in phase III/IV trials of treatments for chronic obstructive pulmonary disease (COPD).
According to the post, the trials examined covered single-inhaler triple therapy and biologic treatments for COPD. The stated aim was to assess how generalisable and equitable these recent trials are.
The post does not give the results of the analysis, the number of trials reviewed or the names of the authors. The Research Letter appears in the November issue of CHEST, and the post links to the full article.
Original source
“to assess how generalizable and equitable these recent trials are”
— CHEST View the post on X
